NovaBay Pharmaceuticals, Inc Stock Prediction and Forecast [NBY]

AI-generated source summary

NovaBay Pharmaceuticals (NBY) shows several positive signals, including short-term and long-term moving average buy signals, and a recent pivot bottom formation. The stock's RSI is at 88, indicating potential overbought conditions and increased risk. While the stock has experienced significant daily movements and has a high weekly volatility of 50.63%, suggesting a very high risk profile, recent insider buying activity and a strong upward trend indicate potential for further gains. However, due to some technical weaknesses and the current overvalued price-to-earnings ratio, the stock is considered a hold candidate, with a projected opening price down $2.94 to $16.22 on Monday, January 12th, 2026. Potential support levels are identified at $9.27 and $3.91. Trading below these levels would signal a sell. Future price action is uncertain, with a projected range between $3.14 and $19.82 over the next year.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   10 Jan 2026, 04:31 UTC

   The analyst published the original source item.

2. First prediction resolved

   12 Jan 2026, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   12 Jan 2026, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.